Gary Patou
Director/Board Member at XENON PHARMACEUTICALS INC.
Net worth: 1 M $ as of 2024-03-30
Profile
Gary Patou is currently working as an Independent Director at Xenon Pharmaceuticals, Inc., Director & Chief Medical Officer at Biointervene, Inc., Advisor at Scleroderma Research Foundation, and Chief Medical Officer at Star Therapeutics, Inc. He previously worked as President & Chief Executive Officer at Cerimon Pharmaceuticals, Inc., Director at Ligand UK Ltd., Senior VP, Director-Project & Portfolio Management at GSK Plc and Smithkline Beecham Pharmaceuticals Ltd., Chief Medical Officer & Executive Vice President at Oscient Pharmaceuticals Corp., President at Genesoft Pharmaceuticals, Inc., Chief Medical Officer at Peplin Ltd.
and Cerimon Pharmaceuticals, Inc., Senior Medical Advisor at Chiasma, Inc., Advisor at MPM BioImpact, Inc., and Chief Medical Officer at Pacira Biosciences, Inc., True North Therapeutics, Inc., and Blade Therapeutics, Inc. He completed his undergraduate, graduate, and doctorate degrees from the University of London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-12-13 | 28,475 ( 0.04% ) | 1 M $ | 2024-03-30 |
Gary Patou active positions
| Companies | Position | Start |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Director/Board Member | 2003-12-31 |
Star Therapeutics, Inc.
 Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | 2020-07-31 |
Biointervene, Inc.
 Biointervene, Inc. Pharmaceuticals: MajorHealth Technology Biointervene, Inc. operates as a biopharmaceutical company. The company was founded by Gary J. Bennett and Daniela Salvemini in 2014 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 2018-12-31 |
Scleroderma Research Foundation
 Scleroderma Research Foundation BiotechnologyHealth Technology The Scleroderma Research Foundation is a non-profit organization that funds research for scleroderma, a potentially life-threatening illness. The non-profit company is based in San Francisco, CA. Established in 1987 by a patient-turned-activist, the foundation is the largest investor in scleroderma research. The foundation's goal is to find a cure for the disease by bringing together the best minds in science. The SRF has invested over $39 million dollars to date in scleroderma research, funding and facilitating research at top institutions such as Johns Hopkins University School of Medicine, Stanford University, and the University of California. | Consultant / Advisor | 2020-12-31 |
Former positions of Gary Patou
| Companies | Position | End |
|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Consultant / Advisor | 2022-07-29 |
| CHIASMA, INC. | Chief Tech/Sci/R&D Officer | 2020-11-30 |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 2020-11-30 |
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 2017-05-31 |
| PACIRA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2015-08-18 |
Training of Gary Patou
| University of London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| GSK PLC | Health Technology |
| PACIRA BIOSCIENCES, INC. | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| Private companies | 13 |
|---|---|
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
| Genesoft Pharmaceuticals, Inc. | Commercial Services |
Peplin Ltd.
 Peplin Ltd. Pharmaceuticals: OtherHealth Technology Peplin Ltd. provides development and commercialisation of prescription human therapeutic products for the treatment of cancer. It also provides drug development process, clinical development and pre-clinical development services. It was was founded in 1998 and is located in Newstead, Australia | Health Technology |
Cerimon Pharmaceuticals, Inc.
 Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Health Technology |
Chiasma, Inc.
 Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Scleroderma Research Foundation
Scleroderma Research Foundation BiotechnologyHealth Technology The Scleroderma Research Foundation is a non-profit organization that funds research for scleroderma, a potentially life-threatening illness. The non-profit company is based in San Francisco, CA. Established in 1987 by a patient-turned-activist, the foundation is the largest investor in scleroderma research. The foundation's goal is to find a cure for the disease by bringing together the best minds in science. The SRF has invested over $39 million dollars to date in scleroderma research, funding and facilitating research at top institutions such as Johns Hopkins University School of Medicine, Stanford University, and the University of California. | Health Technology |
| Smithkline Beecham Pharmaceuticals Ltd. | |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Commercial Services |
Biointervene, Inc.
Biointervene, Inc. Pharmaceuticals: MajorHealth Technology Biointervene, Inc. operates as a biopharmaceutical company. The company was founded by Gary J. Bennett and Daniela Salvemini in 2014 and is headquartered in San Diego, CA. | Health Technology |
Star Therapeutics, Inc.
Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Health Technology |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Gary Patou
